2350202
Project Grant
Overview
Grant Description
SBIR Phase I: Detecting clinical trial communication behavior and preference patterns at a large scale to predict and improve clinical trial participant retention.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project may be to improve the success rates of clinical trials by possibly enhancing the engagement and retention of participants.
Poor clinical trial communication causes participant disengagement and attrition, resulting in incomplete data, failed trials, and associated economic losses for the pharmaceutical industry.
The dynamic communication behavior prediction tools that will be developed by this research may improve participant engagement through tailored communication strategies.
This technology combines unsupervised machine learning and operations research models to predict participant communication and optimize contact protocols to increase engagement and retention.
This is a data-driven approach to improve clinical trial decision-making, schedule flexibility, and participant outcomes, and reduce no-shows and dropout rates.
This Small Business Innovation Research (SBIR) Phase I project will develop a large language model that will improve the communication between clinical researchers and the participants in clinical trials with a focus on optimizing engagement and retention to prevent trial failures.
The project will use cluster analysis of communications data from several clinical trials to understand and model group behavior for key variable detection.
These data will be integrated to design customized communication strategies for identified behavioral clusters.
The clustering and group assignment models will be tuned to develop a synergistic model for employing optimal communication with clinical trial participants.
Increased research staff productivity, improved data collection efficiency, and advances in clinical trial research scientific and technological understanding are predicted.
This new technology could solve a major problem in the industry, improve patient outcomes, decrease healthcare costs, and increase the success rate of clinical trials by achieving response rates close to 95% total participation.
The ultimate goal is to improve treatment efficacy and healthcare delivery quality by incorporating a multi-objective machine learning methodology to increase patient engagement in their care.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project may be to improve the success rates of clinical trials by possibly enhancing the engagement and retention of participants.
Poor clinical trial communication causes participant disengagement and attrition, resulting in incomplete data, failed trials, and associated economic losses for the pharmaceutical industry.
The dynamic communication behavior prediction tools that will be developed by this research may improve participant engagement through tailored communication strategies.
This technology combines unsupervised machine learning and operations research models to predict participant communication and optimize contact protocols to increase engagement and retention.
This is a data-driven approach to improve clinical trial decision-making, schedule flexibility, and participant outcomes, and reduce no-shows and dropout rates.
This Small Business Innovation Research (SBIR) Phase I project will develop a large language model that will improve the communication between clinical researchers and the participants in clinical trials with a focus on optimizing engagement and retention to prevent trial failures.
The project will use cluster analysis of communications data from several clinical trials to understand and model group behavior for key variable detection.
These data will be integrated to design customized communication strategies for identified behavioral clusters.
The clustering and group assignment models will be tuned to develop a synergistic model for employing optimal communication with clinical trial participants.
Increased research staff productivity, improved data collection efficiency, and advances in clinical trial research scientific and technological understanding are predicted.
This new technology could solve a major problem in the industry, improve patient outcomes, decrease healthcare costs, and increase the success rate of clinical trials by achieving response rates close to 95% total participation.
The ultimate goal is to improve treatment efficacy and healthcare delivery quality by incorporating a multi-objective machine learning methodology to increase patient engagement in their care.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Juan,
Puerto Rico
00907-3949
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/25 to 12/31/25 and the total obligations have increased 7% from $273,188 to $293,188.
Docare was awarded
Project Grant 2350202
worth $293,188
from National Science Foundation in September 2024 with work to be completed primarily in San Juan Puerto Rico United States.
The grant
has a duration of 1 year 3 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Detecting clinical trial communication behavior and preference patterns at a large scale to predict and improve clinical trial participant retention
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project
may be to improve the success rates of clinical trials by possibly enhancing the engagement and retention of participants.
Poor clinical trial communication causes participant disengagement and attrition, resulting in incomplete data,
failed trials, and associated economic losses for the pharmaceutical industry The dynamic communication behavior
prediction tools that will be developed by this research may improve participant engagement through tailored
communication strategies. This technology combines unsupervised machine learning and operations research
models to predict participant communication and optimize contact protocols to increase engagement and
retention. This is a data-driven approach to improve clinical trial decision-making, schedule flexibility,
and participant outcomes, and reduce no-shows and dropout rates.
This Small Business Innovation Research (SBIR) Phase I project will develop a large language model that will
improve the communication between clinical researchers and the participants in clinical trials with a focus on
optimizing engagement and retention to prevent trial failures. The project will use cluster analysis of
communications data from several clinical trials to understand and model group behavior for key variable
detection. These data will be integrated to design customized communication strategies for identified
behavioral clusters. The clustering and group assignment models will be tuned to develop a synergistic model
for employing optimal communication with clinical trial participants. Increased research staff productivity,
improved data collection efficiency, and advances in clinical trial research scientific and technological
understanding are predicted. This new technology could solve a major problem in the industry,
improve patient outcomes, decrease healthcare costs, and increase the success rate of clinical trials by
achieving response rates close to 95% total participation. The ultimate goal is to improve treatment efficacy
and healthcare delivery quality by incorporating a multi-objective machine learning methodology to increase
patient engagement in their care.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
DH
Solicitation Number
NSF 23-515
Status
(Ongoing)
Last Modified 8/12/25
Period of Performance
9/15/24
Start Date
12/31/25
End Date
Funding Split
$293.2K
Federal Obligation
$0.0
Non-Federal Obligation
$293.2K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2350202
Additional Detail
Award ID FAIN
2350202
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
WMB7JVTTP6X1
Awardee CAGE
87HP0
Performance District
PR-98
Modified: 8/12/25